Deutsche Bank Maintains a 'Hold' on Laboratory Corporation of America (LH); Leveraged Buy-out Model
Tweet Send to a FriendGet Alerts LH Hot Sheet
Price: $98.97 +1.32%
Rating Summary:
4 Buy, 18 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
4 Buy, 18 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade LH Now!
Deutsche Bank maintains a 'Hold' on Laboratory Corporation of America (NYSE: LH) price target of $94.00.
Deutsche analyst said, "Although we are not in a position to verify the Mergermarket story, we are in a position to respond to these press reports from an analytical framework...We figure LH shareholders would require a premium of at least 15%-25% suggesting a take-out range of $95-$105 for an EV/EBITDA of 9x-10x (vs. current 7.6x 2012E). Based on our LBO model analysis, we observe the following: (1) The IRR profile of a potential LBO would be acceptable for large PE firms (in the mid/upper-teens to low-20% range). (2) Assumed leverage is in a range of 6x-7x (total debt of $8 billion to $9 billion), and the potential equity check would be ~$4 billion or ~3x 2012E adjusted EBITDA of $1.342 billion. (3) Our LBO model assumes 5-yr revenue CAGR of 2.5%-3% (including modest M&A contribution)..."
Deutsche also thinks long-term buyers are attracted to the name as demand for lab testing increases.
For an analyst ratings summary and ratings history on Laboratory Corporation of America click here. For more ratings news on Laboratory Corporation of America click here.
Shares of Laboratory Corporation of America closed at $84.09 yesterday, with a 52 week range of $74.57-$95.30.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Deutsche analyst said, "Although we are not in a position to verify the Mergermarket story, we are in a position to respond to these press reports from an analytical framework...We figure LH shareholders would require a premium of at least 15%-25% suggesting a take-out range of $95-$105 for an EV/EBITDA of 9x-10x (vs. current 7.6x 2012E). Based on our LBO model analysis, we observe the following: (1) The IRR profile of a potential LBO would be acceptable for large PE firms (in the mid/upper-teens to low-20% range). (2) Assumed leverage is in a range of 6x-7x (total debt of $8 billion to $9 billion), and the potential equity check would be ~$4 billion or ~3x 2012E adjusted EBITDA of $1.342 billion. (3) Our LBO model assumes 5-yr revenue CAGR of 2.5%-3% (including modest M&A contribution)..."
Deutsche also thinks long-term buyers are attracted to the name as demand for lab testing increases.
For an analyst ratings summary and ratings history on Laboratory Corporation of America click here. For more ratings news on Laboratory Corporation of America click here.
Shares of Laboratory Corporation of America closed at $84.09 yesterday, with a 52 week range of $74.57-$95.30.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Novartis (NVS) has no intention of pursing a bid for Actavis, Inc. (ACT)
- Apple (AAPL) Streaming Music Service Could be Delayed - The Verge
Create E-mail Alert Related Categories
Analyst Comments, Mergers and Acquisitions, Rumors, Trader TalkRelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
